Literature DB >> 15564485

Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression.

Ilaria Malanchi1, Rosita Accardi, Frank Diehl, Anouk Smet, Elliot Androphy, Jörg Hoheisel, Massimo Tommasino.   

Abstract

We show that E6 proteins from benign human papillomavirus type 1 (HPV1) and oncogenic HPV16 have the ability to alter the regulation of the G(1)/S transition of the cell cycle in primary human fibroblasts. Overexpression of both viral proteins induces cellular proliferation, retinoblastoma (pRb) phosphorylation, and accumulation of products of genes that are negatively regulated by pRb, such as p16(INK4a), CDC2, E2F-1, and cyclin A. Hyperphosphorylated forms of pRb are present in E6-expressing cells even in the presence of ectopic levels of p16(INK4a). The E6 proteins strongly increased the cyclin A/cyclin-dependent kinase 2 (CDK2) activity, which is involved in pRb phosphorylation. In addition, mRNA and protein levels of the CDK2 inhibitor p21(WAF1/CIP1) were strongly down-regulated in cells expressing E6 proteins. The down-regulation of the p21(WAF1/CIP1) gene appears to be independent of p53 inactivation, since HPV1 E6 and an HPV16 E6 mutant unable to target p53 were fully competent in decreasing p21(WAF1/CIP1) levels. E6 from HPV1 and HPV16 also enabled cells to overcome the G(1) arrest imposed by oncogenic ras. Immunofluorescence staining of cells coexpressing ras and E6 from either HPV16 or HPV1 revealed that antiproliferative (p16(INK4a)) and proliferative (Ki67) markers were coexpressed in the same cells. Together, these data underline a novel activity of E6 that is not mediated by inactivation of p53.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564485      PMCID: PMC533917          DOI: 10.1128/JVI.78.24.13769-13778.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Production of high-titer helper-free retroviruses by transient transfection.

Authors:  W S Pear; G P Nolan; M L Scott; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

2.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

3.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

4.  Inhibition of ras-induced proliferation and cellular transformation by p16INK4.

Authors:  M Serrano; E Gómez-Lahoz; R A DePinho; D Beach; D Bar-Sagi
Journal:  Science       Date:  1995-01-13       Impact factor: 47.728

5.  Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition.

Authors:  Ilaria Malanchi; Sandra Caldeira; Maja Krützfeldt; Marianna Giarre; Marianna Alunni-Fabbroni; Massimo Tommasino
Journal:  Oncogene       Date:  2002-08-22       Impact factor: 9.867

6.  Manufacturing DNA microarrays from unpurified PCR products.

Authors:  Frank Diehl; Boris Beckmann; Nadine Kellner; Nicole C Hauser; Susanne Diehl; Jörg D Hoheisel
Journal:  Nucleic Acids Res       Date:  2002-08-15       Impact factor: 16.971

7.  Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.

Authors:  S N Khleif; J DeGregori; C L Yee; G A Otterson; F J Kaye; J R Nevins; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

8.  Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb.

Authors:  Y Li; M A Nichols; J W Shay; Y Xiong
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

9.  The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties.

Authors:  Sandra Caldeira; Ingeborg Zehbe; Rosita Accardi; Ilaria Malanchi; Wen Dong; Marianna Giarrè; Ethel-Michele de Villiers; Raffaele Filotico; Petra Boukamp; Massimo Tommasino
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.

Authors:  G M Clifford; J S Smith; M Plummer; N Muñoz; S Franceschi
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more
  17 in total

1.  E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice.

Authors:  Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

Review 3.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses.

Authors:  Nicholas A Wallace; Denise A Galloway
Journal:  Semin Cancer Biol       Date:  2014-01-08       Impact factor: 15.707

Review 4.  Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Authors:  Adam J Linley; Murrium Ahmad; Robert C Rees
Journal:  Int J Hematol       Date:  2011-03-01       Impact factor: 2.490

5.  Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38.

Authors:  Wen Dong; Ulrich Kloz; Rosita Accardi; Sandra Caldeira; Wei-Min Tong; Zhao-Qi Wang; Lars Jansen; Matthias Dürst; Bakary S Sylla; Lutz Gissmann; Massimo Tommasino
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Expression of human papillomavirus type 16 E7 is sufficient to significantly increase expression of angiogenic factors but is not sufficient to induce endothelial cell migration.

Authors:  Joanna Walker; Lucy Clare Smiley; David Ingram; Ann Roman
Journal:  Virology       Date:  2010-12-14       Impact factor: 3.616

7.  The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.

Authors:  Anny Shai; Tiffany Brake; Chamorro Somoza; Paul F Lambert
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

Review 8.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

Authors:  Raffaella Ghittoni; Rosita Accardi; Uzma Hasan; Tarik Gheit; Bakary Sylla; Massimo Tommasino
Journal:  Virus Genes       Date:  2009-10-17       Impact factor: 2.332

9.  p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers.

Authors:  Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  Beta human papillomavirus E6 expression inhibits stabilization of p53 and increases tolerance of genomic instability.

Authors:  Nicholas A Wallace; Kristin Robinson; Denise A Galloway
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.